thermalife distributon b$ next agm, page-2

read the annual report and have to say im quite impressed,
the important thing is they mentioned international markets for distribution of thermalife, so major focus ahead.
upgraded their facilities which will save time and increae efficiancy.
got a technical team who is familier with regulatory clearances in both aust, UK and US... again a major advantage to expand products internationally.
lastly the line extensions of savatac and red is now the focus as they are in development.
revenue will be generated, less dilution and more value for shareholders as the company can grow more rapidly.
tripoptofen not much mention..
to me its definatly a strong buy with a mc of 7m.